Apyx Medical raises FY2026 revenue guidance after 32% Q1 sales jump
Apyx Medical reported first-quarter revenue of $12.5 million, up 32.4% from $9.4 million, driven by 36% Surgical Aesthetics growth and 13.8% OEM gains. Net loss narrowed to $2.1 million, adjusted EBITDA loss improved to $0.3 million and FY2026 revenue guidance was raised to $59–60 million.
1. First-Quarter Financial Results
Apyx Medical generated total revenue of $12.5 million in Q1 2026, marking a 32.4% increase from $9.43 million in Q1 2025. The company recorded a net loss attributable to stockholders of $2.1 million, improved from a $4.2 million loss last year, and an adjusted EBITDA loss of $0.3 million versus $2.4 million previously.
2. Segment Performance
Revenue in the Surgical Aesthetics segment rose 36.1% to $10.7 million, driven by U.S. AYON system sales, international Renuvion generator shipments and increased handpiece volume. OEM segment sales grew 13.8% to $1.8 million on higher volume shipments to existing customers, although this business is expected to decrease over time.
3. International Market Growth
International revenue reached $4.38 million, up 62.9% year-over-year, bolstered by regulatory approval in South Korea for the Apyx One Console in December 2025. South Korea’s cosmetic surgery market, valued at $1.7 billion in 2024 and projected to reach $3.9 billion by 2031, represents a key growth opportunity.
4. Outlook and Guidance
Based on strong Q1 performance, management increased FY2026 total revenue guidance to $59.0–60.0 million. Renuvion also secured its second consecutive NewBeauty award for Best Minimally Invasive Skin Tightener, reinforcing the company’s brand leadership.